NFE2L2 and ovarian cancer: This reporter was used to directly report any transcriptional perturbation of NRF2. We transfected prNRF2 into our ovarian cancer cell lines, repeated the immunotherapeutic combination treatment for 96 h and assayed cells for luciferase activity (Figure 9C).